Abzu and ADViRNA are partnering on siRNA therapeutics development

Abzu (Copenhagen) and ADViRNA (Worcester, MA) are joining forces to develop novel siRNA therapeutics. This collaboration combines Abzu's AI-driven siRNA design platform with ADViRNA's wet-lab expertise from sequence design through in vivo validation.

ADViRNA is a boutique U.S.-based CRO headquartered in Worcester, Massachusetts, specializing in the design, synthesis, and validation of oligonucleotide therapeutics. They offer fast turnaround times, exceptional flexibility, and seamless collaboration from sequence design to in vivo validation. They're trusted by global leaders in RNA Therapeutics to provide the precision and performance to meet the demands of any project.

Abzu's siRNA design platform enables fast in silico design of new, safer RNA therapeutics. The design platform leverages Abzu's QLattice for modelling drug properties and rigorously screening for potential off-target effects to ensure lead candidates are both active and safe, as well as cross-reactive in the desired species.
Together, the partners will launch two co-owned programs - one in dermatology and one in muscle biology - marking Abzu's transition from service provider to biotech while ADViRNA continues to support clients as a CRO in parallel.
"At ADViRNA, our focus has always been delivering RNAi solutions with speed, flexibility, and precision. This partnership with Abzu allows us to extend that mission into joint asset development, building on the trust we've established with global leaders in RNA therapeutics."
- Alexey Wolfson, PhD, MBA, Chief Executive Officer & Chief Scientific Officer, ADViRNA
"ADViRNA has been a trusted partner for Abzu, bringing deep expertise and wet-lab strength. Together we're moving beyond our roles as CROs to co-develop innovative siRNA assets - starting with programs in dermatology and muscle biology. This marks a major step in Abzu's transition from service provider to biotech."
- Martin Kerr, PhD, Head of Business Development & Pharma Partnerships, Abzu

Abzu ApS
Orient Plads 1, 1.
2150 Nordhavn
Denmark.
Victor Galindo

About Abzu.
Abzu® designs better compounds for RNA therapeutics through the use of our proprietary explainable AI, the QLattice® - the cornerstone of our approach.
Abzu's data-driven approach to drug design leverages a suite of predictive models that are trained and validated on data curated by our scientists.
Using AI models that predict drug properties such as activity, cross-reactivity and off-target potential, we design compounds that are more likely to succeed.

Abzu has offices in Copenhagen and Barcelona, and has received €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to Cool VendorTM. For more information, visit www.abzu.ai.

About ADViRNA.
ADViRNA offers a boutique, science-first approach that emphasizes customization, responsiveness, and deep collaboration. Unlike high-volume providers, they tailor every project from the ground up, from target selection and oligo design to assay development and data interpretation. ADViRNAs clients work directly with the same scientific team throughout the project, ensuring continuity, transparency, and rapid feedback.

ADViRNA is structured to move quickly without sacrificing quality, and their in-house capabilities allow them to deliver high-quality data with shorter timelines and more competitive pricing than many larger providers. Most importantly, they don't just deliver raw data-they help you interpret results, troubleshoot challenges, and strategically plan next steps based on your scientific and therapeutic goals.

This release was published on openPR.